BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 18073064)

  • 1. [A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period].
    Yang Q; Gong ZJ; Hu DF
    Zhonghua Gan Zang Bing Za Zhi; 2007 Nov; 15(11):821-4. PubMed ID: 18073064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period].
    Yang Q; Gong ZJ; Hu DF
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):515-9. PubMed ID: 19912686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A clinical study of adefovir dipivoxil, made in China, for treatment of hepatitis B e antigen-positive patients with chronic hepatitis B].
    Lin XH; Si CW; Yu YY; Li J; Chen XY; Ren XM; Liu P; Zhang SL; Kang XP
    Zhonghua Gan Zang Bing Za Zhi; 2006 Dec; 14(12):898-901. PubMed ID: 17196132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [One-year combination therapy de novo of adefovir dipivoxil and lamivudine for decompensated cirrhosis related to HBV].
    Mo GS; Wu ZL; Zhang JL; Hhang ZG; Cai JG; Jie ZH; Wu XG; Shi JP
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Apr; 25(2):129-31. PubMed ID: 21863638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
    Moon JH; Cho M; Yoon KT; Bae JH; Heo J; Kim GH; Kang DH; Song GA
    Korean J Hepatol; 2008 Dec; 14(4):503-12. PubMed ID: 19119245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
    Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N
    J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
    Xing J; Han T; Liu L; Li Y; Li J; Li Y; Xiao SX
    Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):828-32. PubMed ID: 22433304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and safety of adefovir dipivoxil in patients with decompensated liver cirrhosis with Lamivudine resistance compared to patients with compensated liver disease].
    Moon W; Choi MS; Moon YM; Paik SW; Lee JH; Koh KC; Yoo BC; Rhee JC; Shim SG
    Korean J Hepatol; 2005 Jun; 11(2):125-34. PubMed ID: 15980671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis.
    Choe WH; Kwon SY; Kim BK; Ko SY; Yeon JE; Byun KS; Kim GH; Lee CH
    Liver Int; 2008 Jul; 28(6):814-20. PubMed ID: 18312291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
    N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
    Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Brosgart CL; Borroto-Esoda K; Arterburn S; Chuck SL;
    Gastroenterology; 2006 Dec; 131(6):1743-51. PubMed ID: 17087951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis.
    Peng H; Liu J; Yang M; Tong S; Yin W; Tang H; Hu P; Hu H; Ren H
    J Clin Pharmacol; 2014 Feb; 54(2):189-200. PubMed ID: 24105676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
    Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Arterburn S; Xiong S; Currie G; Brosgart CL;
    N Engl J Med; 2005 Jun; 352(26):2673-81. PubMed ID: 15987916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
    Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
    Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.
    Lampertico P; ViganĂ² M; Manenti E; Iavarone M; Lunghi G; Colombo M
    Hepatology; 2005 Dec; 42(6):1414-9. PubMed ID: 16317671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
    Marcellin P; Chang TT; Lim SG; Tong MJ; Sievert W; Shiffman ML; Jeffers L; Goodman Z; Wulfsohn MS; Xiong S; Fry J; Brosgart CL;
    N Engl J Med; 2003 Feb; 348(9):808-16. PubMed ID: 12606735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results.
    Schiff E; Lai CL; Hadziyannis S; Neuhaus P; Terrault N; Colombo M; Tillmann H; Samuel D; Zeuzem S; Villeneuve JP; Arterburn S; Borroto-Esoda K; Brosgart C; Chuck S;
    Liver Transpl; 2007 Mar; 13(3):349-60. PubMed ID: 17326221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients].
    Cho JH; Cheong JY; Kang JK; Park JS; Lee MH; Lim NK; Hong SP; Kim SO; Yoo WD; Cho SW
    Korean J Hepatol; 2008 Mar; 14(1):58-66. PubMed ID: 18367858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of the 96-week adefovir dipivoxil therapy in patients with chronic hepatitis B].
    Xu Z; Chen LB; Cao H; Shu X; Xu QH; Li G; Xie QF
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Jun; 24(3):224-6. PubMed ID: 21186534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.